Addiction

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

Staff December 19, 2022

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...

Telehealth An Effective Way To Treat Opioid-Use Disorder And Increase Access To Care, According To Peer-Reviewed Study From Bicycle Health

Staff December 15, 2022

BMJ Innovations study finds that Bicycle Health’s telehealth model of care engages people in treatment sooner and demonstrates higher retention...

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

Staff December 9, 2022

Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executive, is an expert on regulatory issues VANCOUVER, Dec....

Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

Staff December 8, 2022

TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

Staff December 7, 2022

ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative...

RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

Staff December 5, 2022

Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Staff November 29, 2022

- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business...

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Staff November 23, 2022

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"),...

Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference

Staff November 23, 2022

CHATHAM, N.J., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...

BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

Staff November 22, 2022

ANAHEIM, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

Staff November 17, 2022

One of six total abstracts accepted highlighting benefits of the SPRINT® PNS SystemCLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At...

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Staff November 17, 2022

NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...

Bicycle Health Announces Significant Milestones for 2022, Laying the Foundation for Long-term Growth

Staff November 15, 2022

Major payor partnerships, a successful Series B, and state expansions helped the company expand access to addiction care to millions...

BioCorRx Provides Business Update for the Third Quarter of 2022

Staff November 15, 2022

ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Staff November 14, 2022

Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate...

Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid

Staff November 3, 2022

NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health...

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

Staff November 3, 2022

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression PatientsBURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022...

QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force

Staff November 1, 2022

The latest recommendations from the U.S. Preventive Services Task Force (USPSTF) indicate that all adults under the age of 65...

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Staff November 1, 2022

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 YearsBURLINGTON, Mass. and JERUSALEM, Nov. 01,...

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

Staff October 31, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage...